Day: May 13, 2024

VANCOUVER, British Columbia, May 13, 2024 (GLOBE NEWSWIRE) — Imperial Metals Corporation (the “Company”) (TSX:III) reports financial results for the three months ended March 31, 2024. QUARTER HIGHLIGHTS FINANCIAL Adjusted EBITDA increased by $4.4 million to $10.3 million in Q1 2024 compared to $5.9 million in Q1 2023. Total revenue was $84.6 million in the March 2024 quarter compared to $92.7 million in the 2023 comparative quarter. In the March 2024 quarter, Mount Polley mine had 1.3 concentrate shipments (2023-1.4 concentrate shipments). The Red Chris mine (100% basis) had 4.0 concentrate shipments (2023-2.4 concentrate shipments). Variations in revenue are impacted by the timing and quantity of concentrate shipments, metal prices and exchange rates, and period end revaluations of revenue attributed to concentrate shipments where...

STRONG SEQUENTIAL SAME-STORE NOI AND NAV GROWTHDECLINING AFFO PAYOUT RATIO75% OF 2024 MORTGAGE MATURITIES REFINANCED TORONTO, May 13, 2024 (GLOBE NEWSWIRE) — Firm Capital Property Trust (“FCPT” or the “Trust”), (TSX: FCD.UN) is pleased to report its financial results for the three months ended March 31, 2024. PROPERTY PORTFOLIO HIGHLIGHTS The portfolio consists of 64 commercial properties with a total gross leasable area (“GLA”) of 2,545,858 square feet, five multi-residential complexes comprised of 599 units and four Manufactured Home Communities comprised of 537 units. The portfolio is well diversified and defensive in terms of geographies and property asset types, with 47% of NOI (42% of asset value) comprised of grocery anchored retail followed by industrial at 27% of NOI (31% of asset value). In addition, the portfolio is...

First quarter consolidated revenue improved 8.3% year-over-year, to $115 million Truck Transportation segment delivered 15.5% revenue growth over Q1 2023, fueled by contribution from asset-based expansion in the United States After quarter-end, the Company strengthened its balance sheet through the sale of non-core, unused land assets for gross proceeds of $4.5 millionBOLTON, Ontario, May 13, 2024 (GLOBE NEWSWIRE) — Titanium Transportation Group Inc. (“Titanium” or the “Company”) (TSX:TTNM, OTCQX:TTNMF), a leading provider of transportation and logistics services throughout North America, is pleased to report its financial results for the three-month period ended March 31, 2024. All amounts are in Canadian currency. Q1 2024 Financial Highlights Compared with Q1 2023Consolidated revenue of $115 million,...

MORRISVILLE, N.C., May 13, 2024 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA) today reported financial results for the first quarter ended March 31, 2024. The company will host a webcast at 8:30 a.m. ET on May 14, 2024 to discuss the financial results and provide a corporate update. Dr. Roger Jeffs, Liquidia’s chief executive officer, said: “We continue to vigorously pursue final agency action for YUTREPIA’s approval for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). And as we have shown, we will remain relentless in the defense of our freedom to go to market despite the myriad of legal filings by our competitor. At our core is our steadfast commitment to deliver YUTREPIA to patients with PAH and PH-ILD. We feel YUTREPIA can provide an important and...

VANCOUVER, British Columbia, May 13, 2024 (GLOBE NEWSWIRE) — Orezone Gold Corporation (TSX: ORE, OTCQX: ORZCF) (“Orezone” or “Company”) reported its operational and financial results for the first quarter of 2024. The Company will host a conference call and webcast on May 14, 2024 commencing at 8:00am PT to discuss its Q1-2024 results. Additional details are provided at the end of this press release. All dollar amounts are in USD unless otherwise stated and abbreviation “M” means million. Patrick Downey, President and CEO, commented “Our Bomboré mine had another quarter of consistent performance, delivering 30,139 ounces of gold production, mine earnings of $27 million, and positive free cashflow. In addition, we successfully commissioned the powerline connection to the national grid and substantially completed the construction...

VANCOUVER, British Columbia, May 13, 2024 (GLOBE NEWSWIRE) — Lithium Americas (Argentina) Corp. (“Lithium Argentina,” the “Company,” or “LAAC”) (TSX: LAAC) (NYSE: LAAC), today announced first quarter results. HighlightsOperational HighlightsDuring the three months ended March 31, 2024, Caucharí-Olaroz produced approximately 4,500 tonnes of lithium carbonate.The project continues to advance through the ramp up and test higher production levels. In April 2024, a planned shutdown was performed to inspect and improve reliability of the processing plant.Caucharí-Olaroz remains on target to produce 20,000 – 25,000 tonnes of lithium carbonate in 2024.The target remains to reach and maintain a near steady state production level by the end of the year.For 2024, Caucharí-Olaroz expects to be operating cash flow positive...

VANCOUVER, British Columbia, May 13, 2024 (GLOBE NEWSWIRE) — Ascot Resources Ltd. (TSX: AOT; OTCQX: AOTVF) (“Ascot” or the “Company”) is pleased to announce the Company’s unaudited financial results for the three months ended March 31, 2024 (“Q1 2024”), and also to provide a construction update on the Company’s Premier Gold Project (“PGP” or the “project”), located on Nisga’a Nation Treaty Lands in the prolific Golden Triangle of northwestern British Columbia. For details of the unaudited condensed interim consolidated financial statements and Management’s Discussion and Analysis for the three months ended March 31, 2024, please see the Company’s filings on SEDAR+ (www.sedarplus.ca). All amounts herein are reported in $000s of Canadian dollars (“C$”) unless otherwise specified. Q1 2024 AND RECENT HIGHLIGHTSOn May 7, 2024,...

– Investigational New Drug application for non-small cell lung cancer trial with luvelta cleared by U.S. Food and Drug Administration; Phase 2 on track to begin dosing in the second half of 2024 – – Patient expansion phase well underway in Phase 2 study of luvelta in combination with bevacizumab; enrollment is expected to complete in the first half of 2024 – – The randomized portion of REFRαME-O1, the registration-enabling study of luvelta for patients with platinum-resistant ovarian cancer, is active and enrolling – – As of March 31, 2024, Sutro had cash and investments of $267.6 million and shares of Vaxcyte common stock valued at $45.6 million – – In April, Sutro further bolstered its cash position with $75 million in upfront payments and an equity investment from licensing exclusive...

Topline data expected in June 2024 from Phase 2b portion of the IMPAHCT global Phase 2b/Phase 3 clinical trial of AV-101 for pulmonary arterial hypertension (PAH) Enrollment continues into the Phase 3 portion of the IMPAHCT trial of AV-101  Poster to be presented with baseline characteristics of the Phase 2b portion of the IMPAHCT trial at the ATS 2024 Conference on May 21  Cash runway into 2026, based on our current operating plan  WALTHAM, Mass., May 13, 2024 (GLOBE NEWSWIRE) — Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced financial results for the quarter ended March 31, 2024, and recent business highlights. Recent Highlights Topline Data Expected in...

On track to submit NDA in the second half of 2024 for Tonmya™ for fibromyalgia; pre-NDA meeting with FDA scheduled for second quarter 2024 Commercial planning continues for U.S. launch of Tonmya, a potential new first-line, centrally-acting, non-opioid analgesic for the management of fibromyalgia CHATHAM, N.J., May 13, 2024 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced financial results for the first quarter ended March 31, 2024, and provided an overview of recent operational highlights. “Our near-term priority continues to be the submission of our New Drug Application (NDA) for Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the management...